Detail Information of Genetic Polymorphisms
| General Information of Drug Transporter (DT) | |||||
|---|---|---|---|---|---|
| DT ID | DTD0006 Transporter Info | ||||
| Gene Name | SLC22A2 | ||||
| Protein Name | Organic cation transporter 2 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| Genetic Polymorphisms of DT (GPD) | |||||
| Genetic Polymorphism | rs316019 | ||||
| Site of GPD | chr6:160249250 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | A>C | ||||
| Minor Allele Frequency | A=0.1374/688 (Global) | ||||
| Allele A | Click to Show/Hide the Full List of Affected Drugs: 5 Drugs in Total | ||||
| Cisplatin | Drug Info | Neoplasm | Correlated with the decreased ototoxicity risk in patients (compare with allele C) | [ 1], [ 2] | |
| Daunorubicin | Drug Info | Neoplasm | Irrelevant to the likelihood of cardiotoxicity in patients (compare with Allele C) | [ 3] | |
| Doxorubicin | Drug Info | Neoplasm | Irrelevant to the likelihood of cardiotoxicity in patients (compare with Allele C) | [ 3] | |
| Metformin | Drug Info | Healthy Individuals | Irrelevant to the steady-state concentration of metformin in healthy individuals (compare with Allele C) | [ 4] | |
| Anthracyclines | N.A. | Neoplasm | Correlated with the decreased likelihood of cardiotoxicity in patients (compare with allele C) | [ 5] | |
| Allele C | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Cisplatin | Drug Info | Testicular Neoplasm | Irrelevant to the likelihood of ototoxicity in patients (compare with Allele A) | [ 6] | |
| Genotype AC | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Cisplatin | Drug Info | Neoplasm | Correlated with the decreased nephrotoxicity risk in patients (compare with genotype CC) | [ 7] | |
| Genotype CC | Click to Show/Hide the Full List of Affected Drugs: 3 Drugs in Total | ||||
| L-Tryptophan | Drug Info | Depression | Correlated with the increased drug clearance (compare with genotypes AA + AC) | [ 8] | |
| Metformin | Drug Info | Healthy Individuals | Correlated with the increased drug clearance in healthy individuals (compare with genotype AC) | [ 9] | |
| Cisplatin | Drug Info | Neoplasm | Irrelevant to the increased likelihood of nephrotoxicity in patients (compare with genotypes AA + AC) | [ 10] | |
| Genotypes AA + AC | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Platinum compounds | N.A. | Non-Small-Cell Lung Carcinoma | Correlated with the increased severity of drug toxicity in patients (compare with genotype CC); Correlated with the increased severity of toxic liver disease in patients (compare with genotype CC) | [ 11] | |
| References | |||||
| 1 | Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin. Pharmacogenomics J. 2017 Dec;17(6):515-520. | ||||
| 2 | Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity. Pharmacogenomics. 2015;16(4):323-32. | ||||
| 3 | Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer. 2013 Aug;60(8):1375-81. | ||||
| 4 | Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. Eur J Clin Pharmacol. 2015 Jun;71(6):691-697. | ||||
| 5 | Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012 May 1;30(13):1422-8. | ||||
| 6 | Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer. JAMA Oncol. 2017 Nov 1;3(11):1558-1562. | ||||
| 7 | Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther. 2009 Oct;86(4):396-402. | ||||
| 8 | Pharmacogenetics meets metabolomics: discovery of tryptophan as a new endogenous OCT2 substrate related to metformin disposition. PLoS One. 2012;7(5):e36637. | ||||
| 9 | Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects. AAPS J. 2013 Apr;15(2):571-80. | ||||
| 10 | Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms. Pharmacogenomics. 2011 Oct;12(10):1417-27. | ||||
| 11 | Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients. Chin J Cancer. 2016 Sep 2;35(1):85. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.